FindMyKOL
Clinical trialNCT06474520RecruitingInterventional

Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD)

NCT06474520 is an interventional trial sponsored by Tongji Hospital. As of 18 Nov 2026, it is recruiting participants. It studies Bos taurus gallstone preparation in Acute Disseminated Encephalomyelitis, Idiopathic Inflammatory Demyelinating Disease and 3 more conditions. The registry lists an enrollment of 250 participants at 1 site in 1 country. The registry lists a start date of 8 Aug 2024 and a primary completion date of 31 Jul 2029. One of its registered investigators has a FindMyKOL profile.

SponsorTongji Hospital →Enrollment250Acute Disseminated EncephalomyelitisIdiopathic Inflammatory Demyelinating DiseaseMultiple SclerosisMyelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseNeuromyelitis Optica Spectrum Disorder
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06474520
FieldValue
Registry IDNCT06474520
StatusRecruiting
Study typeInterventional trial
Lead sponsorTongji Hospital
Enrollment250
Registered sites1
Countries1
ConditionsAcute Disseminated Encephalomyelitis, Idiopathic Inflammatory Demyelinating Disease, Multiple Sclerosis, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease and Neuromyelitis Optica Spectrum Disorder
DrugsBos taurus gallstone preparation
Start8 Aug 2024
Primary completion31 Jul 2029
Study completion31 Dec 2029
Last update posted20 Sept 2024

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

According to the records of traditional Chinese medicine, CBS has the following functions: clearing the heart, resolving phlegm, promoting bile secretion, and calming the nerves. It can treat fever, coma, delirium, epilepsy, convulsions in children, dental caries, throat swelling, oral sores, carbuncle, and furuncle. The significant pathophysiological process of primary inflammatory demyelinating disease of the central nervous system (hereinafter referred to as IIDD) is the activation of the immune system of the central nervous system and the enhancement of inflammation. It includes several common diseases: multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), myelin oligodendrocyte glycoprotein antibody-related disease (MOGAD), acute disseminated encephalomyelitis (ADEM), concentric sclerosis, tumor-like inflammatory demyelinating disease, etc. Combined with the inspiration brought to us by the above background research, especially bilirubin and bile acid are closely related to intestinal digestive function, and CBS is clinically effective through oral administration by subjects, the investigators speculate that CBS is likely to exert its immune, anti-inflammatory and neuroprotective effects on the brain by changing the intestinal flora and regulating the brain-gut axis. In terms of symptoms, CBS is likely to have the effect of improving the clinical symptoms of IIDD subjects and reducing disability.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China1 site, 1 recruiting
  • Tongji Hospital Affiliated To Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei

    Chuan Qin, MDDaishi Tian, MDJun Xiao, MDKe Fang, MDKe Shang, MDLuo-qi Zhou, MDWei Wang, MD →
    Recruiting

Sites by country

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Bos taurus gallstone preparation
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06474520

Each answer restates registry values shown on this page.

What is NCT06474520?

NCT06474520 is an interventional trial sponsored by Tongji Hospital. It studies Bos taurus gallstone preparation in Acute Disseminated Encephalomyelitis, Idiopathic Inflammatory Demyelinating Disease and 3 more conditions.

Is NCT06474520 recruiting?

As of 18 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT06474520?

The registry names Wei Wang, MD (principal investigator, Tongji Hospital) as the overall official.

Where does NCT06474520 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: China.

Which drugs does NCT06474520 study?

The registered drug and biological interventions are Bos taurus gallstone preparation.

When is NCT06474520 expected to complete?

The registry lists a primary completion date of 31 Jul 2029 and a study completion date of 31 Dec 2029. The sponsor last updated the record on 20 Sept 2024.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.